Purpose of the Study: Daratumumab (DARA), a human CD38 mAb, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for MM. In phase 3 studies, DARA-based regim...
Purpose of the Study: Only 20%-30% of patients with relapsed/ refractory multiple myeloma (RRMM) respond to the next line of treatment, and ultimately most will relapse. Melflufen is a li...
Purpose of the Study: Despite advances in therapy, MM remains incurable. Patients with late-stage relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or daratumumab...
Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...
Introduction / Background / Significance: Background: Despite improvements in outcomes for patients with MM, most will relapse, and survival is poor (Kumar et al. Leukemia. 2017;31:2443)....